PTJ
AGIO icon

Paul Tudor Jones’s Agios Pharmaceuticals AGIO Stock Holding History

Paul Tudor Jones’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44M Buy
65,779
+7,628
+13% +$231K ﹤0.01% 1800
2026
Q1 		$1.97M Sell
58,151
-3,194
-5% -$90.6K ﹤0.01% 1870
2025
Q4 		$1.67M Buy
+61,345
New +$2.15M ﹤0.01% 1934
2025
Q1 		– Sell
-28,553
Closed -$938K – 2994
2024
Q4 		$938K Buy
+28,553
New +$1.34M ﹤0.01% 1772
2024
Q2 		– Sell
-35,734
Closed -$1.04M – 2271
2024
Q1 		$1.04M Buy
35,734
+7,836
+28% +$210K 0.01% 1313
2023
Q4 		$621K Buy
+27,898
New +$625K 0.01% 1678
2023
Q2 		– Sell
-14,755
Closed -$339K – 2377
2023
Q1 		$339K Sell
14,755
-10,810
-42% -$287K 0.01% 1841
2022
Q4 		$718K Buy
25,565
+3,221
+14% +$90.8K 0.01% 1346
2022
Q3 		$632K Sell
22,344
-384
-2% -$10.3K 0.01% 1230
2022
Q2 		$504K Sell
22,728
-56,607
-71% -$1.28M 0.01% 1266
2022
Q1 		$2.31M Sell
79,335
-4,480
-5% -$137K 0.05% 479
2021
Q4 		$2.75M Buy
+83,815
New +$3.37M 0.05% 492
2021
Q2 		– Sell
-7,690
Closed -$397K – 1569
2021
Q1 		$397K Sell
7,690
-17,277
-69% -$856K 0.01% 1214
2020
Q4 		$1.08M Sell
24,967
-31,371
-56% -$1.24M 0.03% 669
2020
Q3 		$1.97M Buy
56,338
+39,493
+234% +$1.73M 0.09% 310
2020
Q2 		$901K Buy
+16,845
New +$780K 0.04% 505
2019
Q4 		– Sell
-13,815
Closed -$448K – 1122
2019
Q3 		$448K Buy
13,815
+4,654
+51% +$193K 0.02% 743
2019
Q2 		$457K Buy
+9,161
New +$490K 0.01% 743
2015
Q3 		– Sell
-1,900
Closed -$211K – 1513
2015
Q2 		$211K Buy
+1,900
New +$205K 0.01% 1318
2015
Q1 		– Sell
-2,061
Closed -$231K – 1428
2014
Q4 		$231K Buy
+2,061
New +$184K 0.01% 1200

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Paul Tudor Jones's AGIO Position: Q2 2026 in Review

Paul Tudor Jones increased its Agios Pharmaceuticals (AGIO) stake by 13% in Q2 2026, buying an estimated $231K and bringing the position to 65,779 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1800.

Paul Tudor Jones first reported a position in AGIO in Q4 2014 and has held it in 20 quarters since. The position peaked at $2.75M in Q4 2021. 236 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Paul Tudor Jones held 65,779 shares of Agios Pharmaceuticals worth $2.44M as of Q2 2026.
  • Paul Tudor Jones bought 7,628 Agios Pharmaceuticals shares in Q2 2026, an estimated $231K.
  • Agios Pharmaceuticals made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1800 holding.
  • Paul Tudor Jones first reported a position in Agios Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
  • Paul Tudor Jones's Agios Pharmaceuticals position peaked at $2.75M in Q4 2021.
  • 236 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.